Globus Medical (NYSE:GMED) Announces FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.950-5.050 for the period, compared to the consensus earnings per share estimate of 5.000. The company issued revenue guidance of $3.1 billion, compared to the consensus revenue estimate of $3.2 billion.

Globus Medical Stock Down 6.9%

Shares of GMED stock traded down $5.97 during trading hours on Thursday, reaching $81.13. The company’s stock had a trading volume of 4,072,738 shares, compared to its average volume of 1,481,716. The firm’s 50 day simple moving average is $77.48 and its 200-day simple moving average is $83.35. The company has a market capitalization of $10.89 billion, a price-to-earnings ratio of 20.75, a PEG ratio of 1.28 and a beta of 0.98. Globus Medical has a fifty-two week low of $60.36 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts predict that Globus Medical will post 4.99 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Royal Bank Of Canada decreased their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, October 1st. UBS Group assumed coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.46.

Insider Buying and Selling at Globus Medical

In related news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James Tobin sold 30,000 shares of Globus Medical stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.